The continuous evaluation of EGFR mutation in EGFR-mutation positive lung cancer patients during EGFR TKI treatment
Not Applicable
Recruiting
- Conditions
- non-small cell lung cancer
- Registration Number
- JPRN-UMIN000037232
- Lead Sponsor
- Advanced Cancer Translational Research Institute
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 100
Inclusion Criteria
Not provided
Exclusion Criteria
disagreed patients and patients carrying HBV or HCV
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To evaluate EGFR mutation status during EGFR TKI treatment
- Secondary Outcome Measures
Name Time Method To evaluate the efficacy of EGFR TKI treatment and EGFR mutation status